Search

Your search keyword '"PASNOOR, M."' showing total 116 results

Search Constraints

Start Over You searched for: Author "PASNOOR, M." Remove constraint Author: "PASNOOR, M."
116 results on '"PASNOOR, M."'

Search Results

2. P277 Long-term safety, tolerability, and efficacy of Efgartigimod in patients with Generalized Myasthenia Gravis: concluding analyses from the ADAPT+ study

3. Comparing Four Medicines to Treat Pain from Cryptogenic Sensory Polyneuropathy—The PAIN-CONTRoLS Study

4. Current treatment practice of Guillain-Barré syndrome

5. ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

6. Consistent improvement with eculizumab across muscle groups in myasthenia gravis

7. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab:subgroup analysis of REGAIN and its extension study

9. International Guillain-Barré Syndrome Outcome Study

10. Current treatment practice of Guillain-Barré syndrome

11. Eculizumab Improves Fatigue in Refractory Generalized Myasthenia Gravis

12. ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

13. Epidemiological evidence for a hereditary contribution to myasthenia gravis: A retrospective cohort study of patients from North America

14. The relationship between deficit in digit span and genotype in nonsense mutation Duchenne muscular dystrophy

21. Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis (Quality of Life Research, (2019), 28, 8, (2247-2254), 10.1007/s11136-019-02148-2)

22. Regional variation of Guillain-Barré syndrome

23. O.33Subcutaneous immunoglobulin in myasthenia gravis: results of a North American open label study

25. International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome

26. International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome

27. Randomized Trial of Thymectomy in Myasthenia Gravis

28. A Genome-wide Association Study of Myasthenia Gravis

29. Multiparametric Iterative Self-Organizing MR Imaging Data Analysis Technique for Assessment of Tissue Viability in Acute Cerebral Ischemia

30. LB0002 Safety and Tolerability of Arimoclomol in Patients with Sporadic Inclusion Body Myositis: A Randomised, Double-Blind, Placebo-Controlled, Phase IIa Proof-of-Concept Trial

33. P.044 Efficacy, safety, and tolerability of efgartigimod in AChR-Ab– patients with Generalized Myasthenia Gravis: interim analysis of ADAPT/ADAPT+

34. P.043 Long-term safety, tolerability, and efficacy of efgartigimod in patients with Generalized Myasthenia Gravis: concluding analyses from ADAPT+

35. P.034 Minimal symptom expression following treatment with efgartigimod in patients with Generalized Myasthenia Gravis

36. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis

37. Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double-blind, placebo-controlled trial.

38. Resistance exercise in early-stage ALS patients, ALSFRS-R, Sickness Impact Profile ALS-19, and muscle transcriptome: a pilot study.

39. Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis.

40. Myasthenia gravis.

41. The effect of type 2 diabetes and diabetic peripheral neuropathy on predictive grip force control.

42. Conducting a bayesian multi-armed trial with response adaptive randomization for comparative effectiveness of medications for CSPN.

43. Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial.

44. Phase 2 trial in acetylcholine receptor antibody-positive myasthenia gravis of transition from intravenous to subcutaneous immunoglobulin: The MGSCIg study.

45. CIDP prognosis in patients with IVIG treatment-related fluctuations.

46. A secondary analysis of PAIN-CONTRoLS: Pain's impact on sleep, fatigue, and activities of daily living.

47. Non-dystrophic myotonia: 2-year clinical and patient reported outcomes.

48. Open-label pilot study of ranolazine for cramps in amyotrophic lateral sclerosis.

49. IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis.

50. Quantifying Treatment-Related Fluctuations in CIDP: Results of the GRIPPER Study.

Catalog

Books, media, physical & digital resources